Financial
Aspen building momentum in Commercial Pharmaceuticals and Manufacturing strategy modified
Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with
Filter By:
Aspen Pharmacare Holdings has reported financial results for the year ended 30 June 2025, with
The true heroes of our Mandela Day campaign are our employees who continue to volunteer
Durban, South Africa – JSE-listed Aspen Pharmacare Holdings Limited, a global multinational specialty pharmaceutical company, has announced that Aspen Global Incorporated (“AGI”), its wholly owned
Aspen announces contract manufacturing agreement to initiate local production of Human Insulin for Novo Nordisk at its Gqeberha based sterile manufacturing facility Durban, South Africa
Subject to approval from relevant Competition Authorities, Lilly will enter a strategic agreement with Aspen to continue serving patients and bring innovative therapies to South
Dubai, United Arab Emirates – Aspen Healthcare FZ LLC (“Aspen Healthcare”), a subsidiary of Aspen Pharmacare Holdings Limited (“Aspen”), a global specialty and branded multinational
New funding supports technology transfer from Serum Institute to Aspen to manufacture routine vaccines in Africa, for Africa Collaboration supports sustainable manufacturing capacity for African-produced
Durban, South Africa – JSE Limited listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, is pleased to announce that one of its wholly-owned South
Durban – JSE listed company Aspen Pharmacare Holdings Limited (Aspen), a global multinational specialty pharmaceutical company, is positively positioned to respond as a third party
“With the conclusion of this agreement, our vision for Africa’s own vaccine has become a reality,” said Stephen Saad, Aspen Group Chief Executive.
Aspen Holdings
www.aspenpharma.com
Hotline (South Africa)
0800 122 912
Medical Careline (South Africa) 0800 118 088
Shauneen Beukes
Group Communications Consultant
+27 31 580 8600
+27 82 389 8900
sbeukes@aspenpharma.com
